Novo reports on November 4. Sydbank keeps its buy rating but expects ongoing pressure from pricing and competition, per Investseekers.
Recap by typeshit. Post by Investseekers on X.
A short Facebook share with no context on who used the peptides, where it happened or what followed.
Benzinga notes a 1.89% after-hours gain for Lilly stock, with Novo Nordisk also tagged. No further detail on what drove the move.
Mikhail Varshavski tells Fox News why protein matters, especially for GLP-1 users. He has a paid partnership with Quest Nutrition.
2:07:50
A live Q&A session covering GLP-1 drugs including Zepbound, Wegovy and Foundayo, with the host taking questions from viewers.
Drugs.com
Researchers in Seoul found 10-year cancer rates rose from 1.8% at normal weight to 2.6% with severe obesity, with belly fat showing the highest rates.
10:16
Froese compares the growth hormone releasing peptide tesamorelin with Lilly's experimental retatrutide and asks how the two might fit together.
Loading…